Moderna and Merck Report 42% Reduction in Cancer Deaths and Recurrence with mRNA Vaccine
Breakthrough in Personalized Melanoma Treatment
A new tailored mRNA vaccine named intismeran (or mRNA-4157) is set to revolutionize treatment for melanoma patients. This innovative vaccine employs synthetic mRNA to encode genetic information for up to 34 unique mutations found in a patient’s cancer cells. Researchers are leveraging genetic data by comparing cancerous cells with healthy ones to identify specific mutations that can enhance the immune system’s ability to target and attack cancer cells selectively.
The recent clinical trial focused on two key metrics: “recurrence-free survival” (RFS), which measures the duration a patient remains free from cancer relapse, and “distant metastasis-free survival” (DMFS), which assesses the time without recurrences in other parts of the body.
According to a press release, participants who received the intismeran-Keytruda combination therapy experienced a significant 42% reduction in their risk of recurrence or death compared to those who only received Keytruda alongside a placebo. After a two-year period, 82% of patients in the intismeran-Keytruda group remained cancer-free, compared to 70% in the Keytruda-placebo group.
When it comes to distant metastasis-free survival, the intismeran-Keytruda regimen demonstrated a 38% reduction in the risk of metastasis or death. At the conclusion of the trial, 88.5% of the intismeran-Keytruda group was alive without distant metastasis, while the placebo group recorded an 80% survival rate without metastasis.
Though the effectiveness of this trial did not quite match a previous five-year Phase 2 study—which reported a 49% reduction in recurrence and a 59% reduction in distant metastasis risks—the results still mark a significant milestone in melanoma treatment. “This trial represents the first Phase 3 study to demonstrate a clinically meaningful improvement in RFS and DMFS over standard-care KEYTRUDA for patients with resected melanoma,” stated Dean Li, president of Merck Research Laboratories, highlighting the importance of this research in improving patient outcomes.
Editor’s Take
This development signifies a major leap forward in the fight against melanoma, underscoring the potential of personalized medicine. By harnessing the power of mRNA technology, we are witnessing a shift towards treatments that could drastically improve survival rates. This could open new avenues for research and development in cancer therapies, ultimately benefiting patients while fostering innovation within the biotechnology sector.
Source: arstechnica.com
